Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anthem BiosciencesNSE:ANTHEM -0.35%25 Return-on-Tangible-Asset is 13.99% as of Jun. 2026, which is 26% below its 10-year median of 18.99. GuruFocus rates NSE:ANTHEM with a GF Score™ of 25/100. The stock has 7 warning signs investors should review. Among 1,415 Biotechnology companies, Anthem Biosciences ranks better than 94.49% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Anthem Biosciences's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹4,798 Mil. Anthem Biosciences's average total tangible assets for the quarter that ended in Jun. 2026 was ₹34,288 Mil. Therefore, Anthem Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 13.99%.
The historical rank and industry rank for Anthem Biosciences's Return-on-Tangible-Asset or its related term are showing as below:
NSE:ANTHEM'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 16.71 Med: 18.99 Max: 25.16
Current: 18.16
During the past 5 years, Anthem Biosciences's highest Return-on-Tangible-Asset was 25.16%. The lowest was 16.71%. And the median was 18.99%.
NSE:ANTHEM's Return-on-Tangible-Asset is ranked better than 94.49% of 1415
companies
in the Biotechnology industry
Industry Median: -35.77
vs NSE:ANTHEM: 18.16
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Anthem Biosciences Return-on-Tangible-Asset Related Terms
Anthem Biosciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Anthem Biosciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ANTHEM vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Anthem Biosciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anthem Biosciences Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anthem Biosciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Anthem Biosciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 13.99% mean?
Anthem Biosciences (NSE:ANTHEM) has a Return-on-Tangible-Asset of 13.99% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Anthem Biosciences and its competitors. This is 26% below median its historical median of 18.99. Over the past decade, Anthem Biosciences' Return-on-Tangible-Asset has ranged from 16.71 to 25.16. According to the industry distribution chart, Anthem Biosciences ranks #78 out of 1415 companies in the Biotechnology industry, placing it in the top 5.5%.
Is Anthem Biosciences' Return-on-Tangible-Asset too high?
Anthem Biosciences' current Return-on-Tangible-Asset of 13.99% is 26% below median its 10-year median of 18.99. Over the past 10 years, this metric has ranged from a low of 16.71 to a high of 25.16. Based on the distribution chart, Anthem Biosciences ranks #78 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Anthem Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Anthem Biosciences' Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anthem Biosciences ranks #78 out of 1415 companies for Return-on-Tangible-Asset. This places Anthem Biosciences in the top 6% of its industry — outperforming the majority of peers. Historically, Anthem Biosciences' own Return-on-Tangible-Asset has ranged from 16.71 to 25.16 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Anthem Biosciences and its competitors. Anthem Biosciences's current Return-on-Tangible-Asset is 13.99%, which is 26% below median its own 10-year median of 18.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthem Biosciences stock overvalued right now?
Anthem Biosciences (NSE:ANTHEM) has a current Return-on-Tangible-Asset of 13.99%. The current Return-on-Tangible-Asset is 13.99%, which is 26% below median its 10-year median of 18.99. Anthem Biosciences' overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Anthem Biosciences (NSE:ANTHEM), the current Return-on-Tangible-Asset is 13.99% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
25GF Score
Get the complete analysis for NSE:ANTHEM
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ANTHEM has been successfully added to your 
